Pluristem Therapeutics Inc.  

(Public, NASDAQ:PSTI)   Watch this stock  
Find more results for psti
3.01
+0.04 (1.35%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.94 - 3.01
52 week 2.85 - 4.63
Open 2.99
Vol / Avg. 0.00/135,636.00
Mkt cap 204.23M
P/E     -
Div/yield     -
EPS -0.45
Shares 67.85M
Beta 1.07
Inst. own 2%
Jul 23, 2014
Pluristem Therapeutics Inc KOL Breakfast Event - 8:00AM EDT - Add to calendar
Jun 23, 2014
Pluristem Therapeutics Inc at Biotechnology Industry Organization (BIO) International Convention
Jun 4, 2014
PLURISTEM LIFE SYS INC at Jefferies Global Healthcare Conference
May 29, 2014
PLURISTEM LIFE SYS INC at Barclays Select Series: Israel Biotech/Medtech Corporate Day
May 28, 2014
Pluristem Therapeutics Inc at Bizportal's Israel Roadmap in the Biotech Sector (Hebrew)
May 11, 2014
PLURISTEM LIFE SYS INC at Oppenheimer Israeli Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -9764.21% -3115.61%
Operating margin -9775.79% -3272.90%
EBITD margin - -3072.31%
Return on average assets -50.04% -36.56%
Return on average equity -58.69% -44.44%
Employees 142 -
CDP Score - -

Address

Building #20 MATAM Advanced Technology Park
HAIFA, 31905
Israel
+972-74-7108600 (Phone)
+972-74-7108765 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stromal cell source. The placental adherent stromal cells (ASCs) are grown in the Company's PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body. It is focusing on clinical indication that the route of administration is intramuscular. This route of administration applicable for several different indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries.

Officers and directors

Zami Aberman Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Yaky Yanay CPA President, Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
Boaz Gur-Lavie Chief Financial Officer, Secretary
Age: 40
Bio & Compensation  - Reuters
Doron Shorrer CPA Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Issac Braun Director
Age: 60
Bio & Compensation  - Reuters
Mark S. Germain Director
Age: 63
Bio & Compensation  - Reuters
Moria Kwiat Director
Age: 34
Bio & Compensation  - Reuters
Hava Meretzki Director
Age: 44
Bio & Compensation  - Reuters